The PREDICT Registry is a study focused on patients with ductal carcinoma in situ (DCIS), a non-invasive breast cancer. The study observes patients who have completed or are eligible for surgery and possibly radiation. Researchers use a test called DCISionRT to help decide on treatments by classifying patients into risk groups. The study is non-interventional, meaning it doesn't provide treatment but collects data over time. Participants will be followed and data collected for up to 10 years, with updates at 5 and 10 years.

Key Points:

• The study lasts up to 10 years with data collected at 5 and 10-year intervals.
• Participants are not given new treatments but observed based on existing care.
• Data is de-identified to protect privacy.

Participants must be 30-85 years old, have a tumor size of less than 6 cm, and have recently been diagnosed. They should not have invasive breast cancer or have had certain treatments or surgeries that might affect the results.